Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY
RESEARCH TOOLSreports
HKMPY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.26 - $58.61
Previous CloseN/A
Volume13.00
Average Volume (3M)0.00
Market Cap
$6.13B
Enterprise Value$12.19B
Total Cash (Recent Filing)$213.00M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)17.1
Beta0.39
Next Earnings
Aug 07, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 21, 2025Dividend Yield3.5%
Share Statistics
EPS (TTM)1.19
Shares Outstanding110,943,230
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.65
Price to Book (P/B)2.40
Price to Sales (P/S)0.00
P/FCF Ratio16.82
Enterprise Value/Market Cap1.99
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit8.92
Enterprise Value/Ebitda4.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Hikma Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
HKMPY FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest stock price was $45.26 and its highest was $58.61 in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Hikma Pharmaceuticals PLC’s market cap is $6.13B.
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Aug 07, 2025 which is in 39 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Feb 26, 2025. The company reported $1.194 earnings per share for the quarter, beating the consensus estimate of N/A by $1.194.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Overvalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Semiannually dividend of $1.559 which represents an annual dividend yield of 3.5%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 110,943,230 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of $1.194 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.853%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in HKMPY
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.70%
12-Months-Change
Fundamentals
Return on Equity
15.87%
Trailing 12-Months
Asset Growth
9.68%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals (HKMPY) is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and non-branded generic medicines. Operating in the healthcare and pharmaceutical sectors, the company provides high-quality medications across various therapeutic areas, including oncology, cardiovascular, diabetes, and pain management. Hikma has a global presence, with a strong footprint in the United States, Europe, and the Middle East and North Africa (MENA) region.
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―